Shares of GTx Inc. (GTXI) are down sharply during morning trading. On news that the FDA has asked for more data about its bone drug Toremifene, the stock gapped open lower on Monday and has added to its losses lately.
The stock is now down $3.94 to $5.03, dropping to a new 52-week low.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.